Logo

Evotec Signs a Five-Year Collaboration with Bayer to Develop Therapies for Polycystic Ovary Syndrome

Share this

Evotec Signs a Five-Year Collaboration with Bayer to Develop Therapies for Polycystic Ovary Syndrome

Shots:

  • Bayer to take care of subsequent clinical development and commercialization. Evotec to receive €6.5M up front- €10M research payments over five years- up to €330M milestones pre-clinical and sales milestones- royalties on sales
  • The companies will supply the drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options. Additionally- the deal will have access to targets partnership between Celmatix and Evotec in Oct 2019  
  • In 2012- Bayer and Evotec signs a five-year multi-target agreement for three clinical and one pre-clinical drug candidates currently involved to treat endometriosis. Additionally- in 2016- the companies collaborated to develop therapies for kidney disease

Click here to read full press release/ article | Ref: Bayer | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions